Abstract
An elevated number of eosinophilis have been implicated in several type 2 inflammmatory chronic diseases that occur at various sites in the body. Over the past 20 years, our knowledge of diseaases associated with increased numbers of eosinophlis has advanced thanks to the developmnet of drugs that can reduce or even eliminate eosinophils.
One such agent is mepolizumab. This article briefly and clearly summarizes the pharmacological profile of mepolizumab and its current indications for a number of chronic eosinophlilic diseases.